Line 71: | Line 71: | ||
Technological advances of the last decade facilitate development of new in vitro diagnostic devices (IVDD). Since these tests may have a high impact on individual and public health, their safety is a major concern. To keep up with scientific and technological progress and with needs of society, European Parliament adopted new regulation on in vitro diagnostic medical devices just few months ago - on 5 April 2017. Australian Therapeutic Goods Administration issued a regulatory framework on 1 July 2010.</p> | Technological advances of the last decade facilitate development of new in vitro diagnostic devices (IVDD). Since these tests may have a high impact on individual and public health, their safety is a major concern. To keep up with scientific and technological progress and with needs of society, European Parliament adopted new regulation on in vitro diagnostic medical devices just few months ago - on 5 April 2017. Australian Therapeutic Goods Administration issued a regulatory framework on 1 July 2010.</p> | ||
<p> | <p> | ||
− | The general trend is the same - new policies are more strict and should promote safety of IVDDs. For example, while the previous directive in EU required only one out of five IVDD to be checked by a Notified Body before it was placed on the market, according to new regulation only safety class A tests (lowest risk) will be sole responsibility of the manfucaturer. All devices of higher risk classes will require involvement of Notified Body. This risk classification of IVDDs is new as well and scheme for performance evaluation during lifetime of a device was introduced. While U.S. system focuses on evidence of clinical efficiency, the FDA rarely requires clinical outcome studies <sup><a class="myLink" href="#ref_1">1</a></sup>; in contrast, new EU regulation introduces new requirements for clinical evidence including clinical data and continous performance evaluation including incident reporting. | + | The general trend is the same - new policies are more strict and should promote safety of IVDDs. For example, while the previous directive in EU required only one out of five IVDD to be checked by a Notified Body before it was placed on the market, according to new regulation only safety class A tests (lowest risk) will be sole responsibility of the manfucaturer. All devices of higher risk classes will require involvement of Notified Body. This risk classification of IVDDs is new as well and scheme for performance evaluation during lifetime of a device was introduced. While U.S. system focuses on evidence of clinical efficiency, the FDA rarely requires clinical outcome studies<sup><a class="myLink" href="#ref_1">1</a></sup>; in contrast, new EU regulation introduces new requirements for clinical evidence including clinical data and continous performance evaluation including incident reporting. |
</p> | </p> | ||
</td> | </td> | ||
Line 103: | Line 103: | ||
<h3>Absence of professional counseling</h3> | <h3>Absence of professional counseling</h3> | ||
− | <p>In case of self-test user does not get immediate counseling from health professional, which may cause possible delayed entry to care<sup><a class="myLink" href="#ref_11">11</a></sup>. Currently available HIV self-tests have limited follow-up options, for example, in U.S. they mostly provide only phone number that participant may call<sup><a class="myLink" href="#ref_8">8</a></sup>. Rather governmental programs of follow-up counseling are required with clear instructions of acting in case of positive test. This study also points out interesting argument, that self-tests also fails to guide users whose tests are negative to prevention services so that they can reduce their future risk for HIV infection <sup><a class="myLink" href="#ref_8">8</a></sup>. As a possible solution self-test devices may be equipped with an Internet of Things module reporting the case with delivery of timely, active follow-up counseling and referrals over the phone <sup><a class="myLink" href="#ref_8">8</a></sup>.</p> | + | <p>In case of self-test user does not get immediate counseling from health professional, which may cause possible delayed entry to care<sup><a class="myLink" href="#ref_11">11</a></sup>. Currently available HIV self-tests have limited follow-up options, for example, in U.S. they mostly provide only phone number that participant may call<sup><a class="myLink" href="#ref_8">8</a></sup>. Rather governmental programs of follow-up counseling are required with clear instructions of acting in case of positive test. This study also points out interesting argument, that self-tests also fails to guide users whose tests are negative to prevention services so that they can reduce their future risk for HIV infection<sup><a class="myLink" href="#ref_8">8</a></sup>. As a possible solution self-test devices may be equipped with an Internet of Things module reporting the case with delivery of timely, active follow-up counseling and referrals over the phone<sup><a class="myLink" href="#ref_8">8</a></sup>.</p> |
<p>Some of users may initiate self-treatment based on results they found on Internet, which may be misleading and harmful for their health.</p> | <p>Some of users may initiate self-treatment based on results they found on Internet, which may be misleading and harmful for their health.</p> | ||
<p>Wrong interpretation of results by badly informed user may cause interrupt of treatment or change of dosages of taken mediacations.</p> | <p>Wrong interpretation of results by badly informed user may cause interrupt of treatment or change of dosages of taken mediacations.</p> |
Revision as of 17:15, 1 November 2017
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|